MEIRAGTX HOLDINGS PLC (MGTX)
KYG596651029 - Common Stock
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024
MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine...
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy...
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene...
MeiraGTx Holdings Breaks Above 200-Day Moving Average - Bullish for MGTX
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023
MGTX stock results show that MeiraGTx Hldgs beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MeiraGTx Hldgs (NASDAQ:MGTX) just reported results for the fourth quarter of 20...
MGTX Crosses Below Key Moving Average Level
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal...
Commit To Purchase MeiraGTx Holdings At $5, Earn 16.4% Annualized Using Options
MeiraGTx announces $50M milestone payment from Janssen (NASDAQ:MGTX)
MeiraGTx Holdings achieves $50M milestone payment from Janssen Pharmaceuticals for initiating LUMEOS extension study.
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP)
Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
/PRNewswire/ -- Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil...
MeiraGTx signs asset purchase agreement for bota-vec collaboration with Janssen (MGTX)
MeiraGTx (NASDAQ:MGTX) said Thursday it signed an asset purchase agreement for the remaining interests in bota-vec, used for the treatment of XLRP,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked...
MeiraGTx to Participate in Upcoming Investor Conferences
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene...
Commit To Buy MeiraGTx Holdings At $5, Earn 20.8% Annualized Using Options
MeiraGTx GAAP EPS of -$0.74, revenue of $5.1M (NASDAQ:MGTX)
MeiraGTx reports Q3 GAAP EPS of -$0.74 and a revenue increase of 5.8% YoY, according to the company's press release.
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 ...
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis on MeiraGTx Holdings plc a vertically integrated, clinical stage gene therapy company.
MeiraGTx reports $30 million strategic investment from Sanofi (NASDAQ:MGTX)
As a financial writer, I can tell you about MeiraGTx's $30 million investment from Sanofi and its pursuit of strategic options.
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
Sanofi to purchase $30 million of ordinary shares of the Company at a price of $7.50 per share Sanofi to receive a right of first negotiation (ROFN) for...